Urologia

OMS | Novo estudo destaca a prevalência global inaceitavelmente alta de sífilis entre homens que fazem sexo com homens.

14 Jul, 2021 | 11:35h

New study highlights unacceptably high global prevalence of syphilis among men who have sex with men – World Health Organization

Estudo original: Prevalence of syphilis among men who have sex with men: a global systematic review and meta-analysis from 2000–20 – The Lancet Global Health

Comentário: Syphilis in men who have sex with men: advancing research and human rights – The Lancet Global Health

---

Estudo randomizado | Ressonância magnética reduz à metade os casos de “overdiagnosis” no rastreamento do câncer de próstata.

9 Jul, 2021 | 15:51h

MRI-Targeted or Standard Biopsy in Prostate Cancer Screening – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comunicado de imprensa: MRI can cut overdiagnoses in prostate-cancer screening by half – Karolinska Institutet

Artigos relacionados: RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer E Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer E Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis E Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management E Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer E Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer E Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy E Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer E Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis E Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer

---

Diretrizes clínicas para sintomas no trato urinário inferior feminino.

8 Jul, 2021 | 09:35h

Clinical Guidelines for Female Lower Urinary Tract Symptoms – International Journal of Urology

---

Estudo randomizado | Lutétio-177-PSMA-617 para metástase de câncer de próstata resistente à castração.

24 Jun, 2021 | 10:50h

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

---

Diagnóstico diferencial de doenças prostáticas incomuns: ressonância magnética multiparamétrica (multi-parametric magnetic resonance imaging – mpMRI) e informação clínica combinadas.

18 Jun, 2021 | 10:25h

Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information – Insights into Imaging

---

Diretriz AUA | Massa renal e câncer renal localizado: avaliação, tratamento e seguimento.

2 Jun, 2021 | 10:16h

Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow Up – American Urological Association

Comentário: AUA updates guideline on renal masses and localized renal cancer – Urology Times

---

M-A: Um programa guiado por biofeedback ou estimulação elétrica da musculatura do assoalho pélvico pode ajudar na recuperação mais rápida da continência urinária após prostatectomia radical.

26 Mai, 2021 | 10:20h

A biofeedback‐guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta‐analysis and systematic review – The International Journal of Clinical Practice

---

Estudo randomizado: Em pacientes com câncer de próstata, a inclusão de 18F-fluciclovina-PET/TC para guiar a radioterapia de resgate pós-protatectomia pode melhorar a sobrevida livre de recorrência ou persistência bioquímica.

10 Mai, 2021 | 10:54h

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link para o resumo – $ para o texto completo)

---

Análise final de sobrevida: Apalutamida em pacientes com câncer de próstata metastático sensível à castração

4 Mai, 2021 | 09:32h

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study – Journal of Clinical Oncology

 

Comentário no Twitter

Just in JCO @ASCO 👉Glad to share final OS data from TITAN trial after ~4 yrs of follow up: unprecedented OS benefit with APALUTAMIDE/ APA after adjusting for crossover from placebo👉48% reduction in risk of death with APA, HR=0.52 👇https://t.co/9ZCoXsTE6x @oncoalert @urotoday pic.twitter.com/FNBFA84DxY

— Neeraj Agarwal (@neerajaiims) April 29, 2021

 

---

Diretriz da AHA: Nos tratamentos de câncer de mama e de próstata que incluem hormonioterapias, é necessário um controle mais rígido do risco cardíaco

29 Abr, 2021 | 10:12h

Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association – Circulation: Genomic and Precision Medicine

Comunicado de Imprensa: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association

Principais tópicos: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association

Comentários: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association E Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association E Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD E Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay

---